Table 1.
General characteristics of patients.
| All (N = 33) |
SOR/NIVO (N = 8) |
SOR/PEMBRO (N = 4) |
LEN/NIVO (N = 11) |
LEN/PEMBRO (N = 10) |
p-Value | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | (IQR) | N | % | M | (IQR) | N | % | M | (IQR) | N | % | M | (IQR) | N | % | M | (IQR) | N | % | |||
| Age (years) | 66 | (14) | 68 | (9) | 70 | (4) | 60 | (18) | 56 | (15) | 0.090 a | |||||||||||
| Gender (male) | 26 | (78.8%) | 6 | (75.0%) | 2 | (50.0%) | 8 | (72.7%) | 10 | (100%) | 0.173 b | |||||||||||
| Hepatitis infection | HBV | 19 | (57.6%) | 4 | (50.0%) | 0 | 8 | (72.7%) | 7 | (70.0%) | 0.063 b | |||||||||||
| HCV | 8 | (24.2%) | 0 | 4 | (100%) | 2 | (18.2%) | 2 | (25.0%) | 0.062 b | ||||||||||||
| Child-Pugh stage | A | 33 | (100%) | 8 | (100%) | 4 | (100%) | 11 | (100%) | 10 | (100%) | 1.000 b | ||||||||||
| BCLC stage | C | 33 | (100%) | 8 | (100%) | 4 | (100%) | 11 | (100%) | 10 | (100%) | 1.000 b | ||||||||||
| MVI | 16 | (48.2%) | 4 | (50.0%) | 6 | (54.5%) | 6 | (60.0%) | 0.215 b | |||||||||||||
| EHS | 19 | (57.6%) | 4 | (50.0%) | 4 | (100%) | 6 | (54.5%) | 5 | (50.0%) | 0.332 b | |||||||||||
| Bilirubin (U/L) | 0.7 | (0.9) | 1.4 | (1.9) | 0.5 | (0.2) | 0.7 | (0.5) | 0.9 | (0.8) | 0.281 a | |||||||||||
| ALT (U/L) | 36 | (34) | 34 | (25) | 15 | (15) | 51 | (45) | 40 | (19) | 0.206 a | |||||||||||
| Abnormal ALT (male > 50 U/L or female > 35 U/L) | 10 | (30.3%) | 2 | (25.0%) | 0 | 6 | (54.5%) | 2 | (20.0%) | 0.144 b | ||||||||||||
| AFP (ng/mL) | 130 | (3115) | 227 | (3408) | 1036 | (2067) | 132 | (3916) | 34 | (7502) | 0.575 a | |||||||||||
| Abnormal AFP (AFP > 7 ng/mL) | 22 | (66.7%) | 6 | (75.0%) | 2 | (50.0%) | 9 | (81.8%) | 5 | (50.0%) | 0.371 b | |||||||||||
| AFP (ng/mL) | ≥400 | 13 | (39.4%) | 2 | (25.0%) | 2 | (50.0%) | 5 | (45.5%) | 4 | (40.0%) | 0.788 b | ||||||||||
| <400 | 20 | (60.6%) | 6 | (75.0%) | 2 | (50.0%) | 6 | (54.5%) | 6 | (60.0%) | ||||||||||||
| AFP decreased > 10% | 10 | (30.3%) | 4 | (50.0%) | 0 | 4 | (36.4%) | 2 | (20.0%) | 0.272 b | ||||||||||||
All p-values were analyzed with Mann–Whitney test a and Pearson’s Chi-square test b. Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; EHS, extrahepatic spread; HBV, Hepatitis B; HCV, Hepatitis C; IQR, interquartile range; LEN, lenvatinib; M, median; MVI, macroscopic vascular invasion; N, number of patients; NIVO, nivolumab; PEMBRO, pembrolizumab; SOR, sorafenib.